129 related articles for article (PubMed ID: 37017194)
1. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.
Kaino A; Niizuma H; Katayama S; Irie M; Nakano T; Sato D; Saito T; Kato S; Suehara Y; Sasahara Y; Kikuchi A
Pediatr Blood Cancer; 2023 Aug; 70(8):e30330. PubMed ID: 37017194
[No Abstract] [Full Text] [Related]
2. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with
Rakheja D; Park JY; Fernandes NJ; Watt TC; Laetsch TW; Collins RRJ
Int J Surg Pathol; 2022 Sep; 30(6):706-715. PubMed ID: 35164578
[TBL] [Abstract][Full Text] [Related]
5. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
6. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
[TBL] [Abstract][Full Text] [Related]
7. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
[TBL] [Abstract][Full Text] [Related]
8. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
10. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
12. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
13. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
14. Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma.
Wood ML; Fanburg-Smith JC; Brian JM; White JC; Powell JL; Freiberg AS
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e184-e187. PubMed ID: 38099690
[TBL] [Abstract][Full Text] [Related]
15. Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
Van Damme E; Kiselinova M; Van Schoote E
Tumori; 2019 Dec; 105(6):NP35-NP37. PubMed ID: 31023173
[TBL] [Abstract][Full Text] [Related]
16. [Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors].
Tenaillon A; Orbach D
Bull Cancer; 2023 Mar; 110(3):248-249. PubMed ID: 36717340
[No Abstract] [Full Text] [Related]
17. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]